In the latest session, CTI BioPharma Corp. (NASDAQ: CTIC) closed at $4.40 down -3.30% from its previous closing price of $4.55. In other words, the price has decreased by -$0.1500 from its previous closing price. On the day, 3599145 shares were traded. CTIC stock price reached its highest trading level at $4.5300 during the session, while it also had its lowest trading level at $4.3050.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
For a deeper understanding of CTI BioPharma Corp.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, SVB Leerink on October 17, 2022, initiated with a Outperform rating and assigned the stock a target price of $13.
On September 01, 2022, Jefferies started tracking the stock assigning a Buy rating and target price of $13.
On July 07, 2022, Cowen started tracking the stock assigning a Outperform rating and target price of $10.Cowen initiated its Outperform rating on July 07, 2022, with a $10 target price.
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 24 when Fong James K sold 100,000 shares for $6.00 per share. The transaction valued at 600,000 led to the insider holds 3,565 shares of the business.
Craig Adam R sold 85,317 shares of CTIC for $511,923 on Jan 24. The President and CEO now owns 29,440 shares after completing the transaction at $6.00 per share. On Jan 03, another insider, Craig Adam R, who serves as the President and CEO of the company, sold 84,683 shares for $6.01 each. As a result, the insider received 509,224 and left with 29,440 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 10.98.
Stock Price History:
Over the past 52 weeks, CTIC has reached a high of $7.80, while it has fallen to a 52-week low of $3.32. The 50-Day Moving Average of the stock is 5.3896, while the 200-Day Moving Average is calculated to be 5.7207.
For the past three months, CTIC has traded an average of 2.96M shares per day and 4.9M over the past ten days. A total of 128.58M shares are outstanding, with a floating share count of 125.91M. Insiders hold about 0.19% of the company’s shares, while institutions hold 79.30% stake in the company. Shares short for CTIC as of Jan 30, 2023 were 12.73M with a Short Ratio of 13.50M, compared to 14.49M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 10.03% and a Short% of Float of 10.81%.
There are 9 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.09 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.11, while EPS last year was -$0.38. The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.02 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.61 and -$0.8 for the fiscal current year, implying an average EPS of -$0.75. EPS for the following year is -$0.01, with 9 analysts recommending between $0.21 and -$0.35.
Based on 9 analysts’ estimates, the company’s revenue will be $153.96M in the next fiscal year. The high estimate is $199.2M and the low estimate is $89.64M. The average revenue growth estimate for next year is up 170.80% from the average revenue estimate for this year.